Prices as of 2026/10/30 close
Company comparison
Medipal is the largest by revenue at ¥3.8T, followed by Alfresa (¥3.1T), Hanwa (¥2.7T) and Yamae (¥1.1T).
Hanwa has the highest operating margin at 2.2%, 1.0 points above the lowest, Alfresa (1.2%).
Revenue growth in the latest results: Yamae +7.8%, Alfresa +4.8%, Hanwa +4.2%, Medipal +4.0%. For next year, Yamae guides for the fastest operating profit growth (+21.7%).
Hanwa pays the most on average (¥9.26M), ¥2.30M more than Yamae (¥6.96M).
Over the past year the shares moved Hanwa +42.4%, Medipal +37.9%, Alfresa +16.4%, Yamae +6.3%.
Head-to-head wins18 metrics
One win per metric for the company with the best value. Metrics with no better or worse (P/E, average age, employees) are excluded.
ScaleInvestors
Medipal aheadMedipal 2 : Alfresa 0 : Hanwa 1 : Yamae 0
Revenue: Medipal ¥3.8T / Alfresa ¥3.1T / Hanwa ¥2.7T / Yamae ¥1.1T
ProfitabilityInvestors
Hanwa aheadMedipal 0 : Alfresa 1 : Hanwa 2 : Yamae 1
Operating margin: Medipal 1.4% / Alfresa 1.2% / Hanwa 2.2% / Yamae 1.7%
GrowthInvestors
Yamae aheadMedipal 0 : Alfresa 0 : Hanwa 2 : Yamae 3
Revenue growth (YoY): Medipal +4.0% / Alfresa +4.8% / Hanwa +4.2% / Yamae +7.8%
Stock & balance sheetInvestors
EvenMedipal 1 : Alfresa 1 : Hanwa 1 : Yamae 0
Share price, 1 year: Medipal +37.9% / Alfresa +16.4% / Hanwa +42.4% / Yamae +6.3%
Pay & workforceJob seekers
Hanwa aheadMedipal 1 : Alfresa 0 : Hanwa 2 : Yamae 0
Average salary: Medipal ¥8.14M / Alfresa ¥8.39M / Hanwa ¥9.26M / Yamae ¥6.96M
| Metric | Medipal | Alfresa | Hanwa | Yamae |
|---|---|---|---|---|
| Revenue | ◎¥3.8T | ¥3.1T | ¥2.7T | ¥1.1T |
| Operating profit | ¥53.2B | ¥36.2B | ◎¥58.4B | ¥18.1B |
| Net income | ◎¥42.5B | ¥41.7B | ¥38.3B | ¥11.1B |
| Metric | Medipal | Alfresa | Hanwa | Yamae |
|---|---|---|---|---|
| Operating margin | 1.4% | 1.2% | ◎2.2% | 1.7% |
| Net margin | 1.1% | 1.3% | ◎1.4% | 1.0% |
| ROE | — | 8.4% | — | ◎11.3% |
| Revenue per employee | ¥20.6B | ◎¥46.3B | ¥1.5B | ¥8.8B |
| Metric | Medipal | Alfresa | Hanwa | Yamae |
|---|---|---|---|---|
| Revenue growth (YoY) | +4.0% | +4.8% | +4.2% | ◎+7.8% |
| Operating profit growth (YoY) | −4.4% | −5.0% | −5.0% | ◎+14.6% |
| Revenue CAGRlast 5 years | +3.5% | — | ◎+8.8% | — |
| Guidance: revenue growthnext FY plan | +3.3% | +1.3% | ◎+12.7% | +10.6% |
| Guidance: op. profit growthnext FY plan | +3.4% | −6.3% | +6.9% | ◎+21.7% |
| Metric | Medipal | Alfresa | Hanwa | Yamae |
|---|---|---|---|---|
| Share price, 1 year | +37.9% | +16.4% | ◎+42.4% | +6.3% |
| Share price, 3 months | ◎+14.6% | +3.4% | +7.5% | −7.4% |
| P/E (trailing)lower = cheaper | — | 10.8x | — | 6.7x |
| Equity ratio | — | ◎33.7% | — | 26.0% |
| Share price (close) | ¥3,441 | ¥2,469 | ¥1,829 | ¥2,690 |
◎ marks the best value for each metric. Revenue and profit are from the latest full-year earnings release; share prices are closing-price references; P/E = latest close ÷ trailing EPS. For banks and some other financials, revenue means ordinary income.
| Metric | Medipal | Alfresa | Hanwa | Yamae |
|---|---|---|---|---|
| Average salary | ¥8.14M | ¥8.39M | ◎¥9.26M | ¥6.96M |
| Starting salary (monthly) | — | — | ◎¥320,000 | ¥285,000 |
| Average tenure | ◎19.8 yrs | 14.0 yrs | 11.5 yrs | 2.7 yrs |
| Average age | 48.6 | 46.6 | 37.4 | 39.3 |
| Employees | 185 | 67 | 1,745 | 123 |
Average salary is for the reporting (parent) company and is affected by average age and job mix. Holding companies with few employees are left out of the salary comparison.
Close (Oct 30, 2026)
¥3,441+37.9% (1Y)
Medipal +37.9% over 1Y. Compared: Alfresa +16.4%, Hanwa +42.4%, Yamae +6.3%.
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Each line shows the % change from the start of the period. Updated Oct 30, 2026.
Medipal3 segments
Alfresa4 segments
Hanwa6 segments
Yamae4 segments
AAverage annual salary from the securities filings: Hanwa ¥9.26M, Alfresa ¥8.39M, Medipal ¥8.14M, Yamae ¥6.96M. Hanwa pays the most. Averages also depend on staff age and job mix, so check the average age too (Medipal 48.6, Alfresa 46.6, Hanwa 37.4, Yamae 39.3).
ARevenue in the latest results: Medipal ¥3.8T, Alfresa ¥3.1T, Hanwa ¥2.7T, Yamae ¥1.1T. Medipal is the largest by revenue at ¥3.8T, followed by Alfresa (¥3.1T), Hanwa (¥2.7T) and Yamae (¥1.1T).
AOperating margins: Hanwa 2.2%, Yamae 1.7%, Medipal 1.4%, Alfresa 1.2%. Hanwa turns the highest share of sales into operating profit.
AShare price change over the past year (closing prices, for reference): Hanwa +42.4%, Medipal +37.9%, Alfresa +16.4%, Yamae +6.3%. Hanwa has risen the most.
Comparing 4 companies (up to 4)
Sources: earnings releases (kessan tanshin), annual securities reports and other public information. Share prices are closing-price references, not real-time. Our data may contain errors; investment decisions are your own responsibility.
